MA37645A2 - Formulations stabilisées contenant des anticorps anti-dll4 - Google Patents

Formulations stabilisées contenant des anticorps anti-dll4

Info

Publication number
MA37645A2
MA37645A2 MA37645A MA37645A MA37645A2 MA 37645 A2 MA37645 A2 MA 37645A2 MA 37645 A MA37645 A MA 37645A MA 37645 A MA37645 A MA 37645A MA 37645 A2 MA37645 A2 MA 37645A2
Authority
MA
Morocco
Prior art keywords
formulations containing
containing anti
dll4 antibodies
stabilized formulations
present
Prior art date
Application number
MA37645A
Other languages
Arabic (ar)
English (en)
Other versions
MA37645A3 (fr
MA37645B1 (fr
Inventor
Scott Walsh
Daniel Dix
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37645(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA37645A2 publication Critical patent/MA37645A2/fr
Publication of MA37645A3 publication Critical patent/MA37645A3/fr
Publication of MA37645B1 publication Critical patent/MA37645B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à un ligand humain delta-like 4 (dll4). Lesdites formulations peuvent contenir, outre un anticorps anti-dll4, un tampon de phosphate, un co-solvant organique, un disaccharide, et un sel. Les formulations pharmaceutiques selon la présente invention présentent un degré substantiel de stabilité d'anticorps après stockage pendant plusieurs mois et après avoir été soumises à une contrainte thermique et à d'autres contraintes physiques.
MA37645A 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4 MA37645B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31
PCT/US2013/043516 WO2013181486A1 (fr) 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4

Publications (3)

Publication Number Publication Date
MA37645A2 true MA37645A2 (fr) 2016-08-31
MA37645A3 MA37645A3 (fr) 2017-07-31
MA37645B1 MA37645B1 (fr) 2018-10-31

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37645A MA37645B1 (fr) 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4

Country Status (30)

Country Link
US (1) US9675692B2 (fr)
EP (1) EP2854849B1 (fr)
JP (1) JP6144758B2 (fr)
KR (1) KR20150033615A (fr)
CN (1) CN104349791A (fr)
AR (1) AR092325A1 (fr)
AU (1) AU2013267301B2 (fr)
BR (1) BR112014028997A2 (fr)
CA (1) CA2872275C (fr)
CL (1) CL2014003237A1 (fr)
CO (1) CO7151478A2 (fr)
DK (1) DK2854849T3 (fr)
EA (1) EA029779B1 (fr)
ES (1) ES2668900T3 (fr)
HK (1) HK1207305A1 (fr)
IL (1) IL235468A0 (fr)
LT (1) LT2854849T (fr)
MA (1) MA37645B1 (fr)
MX (1) MX357146B (fr)
NO (1) NO2887943T3 (fr)
NZ (1) NZ702288A (fr)
PH (1) PH12014502429B1 (fr)
PL (1) PL2854849T3 (fr)
PT (1) PT2854849T (fr)
SG (1) SG11201407171XA (fr)
SI (1) SI2854849T1 (fr)
SM (1) SMT201800216T1 (fr)
TW (1) TWI609696B (fr)
UY (1) UY34842A (fr)
WO (1) WO2013181486A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
EP3207936B1 (fr) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Composition de peptide stable
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
AU2019254473A1 (en) * 2018-04-16 2020-12-03 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
KR20230035595A (ko) * 2020-07-08 2023-03-14 리제너론 파아마슈티컬스, 인크. 항-ctla-4 항체를 함유하는 안정화된 제형

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
WO1993000807A1 (fr) 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP0999853B1 (fr) 1997-06-13 2003-01-02 Genentech, Inc. Formulation stabilisee renfermant un anticorps
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
EP3192528A1 (fr) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation des solutions contenant des anti-corps anti-il-6r comportant un sucre comme stabilisateur
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
WO2005072772A1 (fr) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Compositions pharmaceutiques
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
US8883145B2 (en) * 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
BR112012012080B1 (pt) 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
EP2542582A4 (fr) 2010-03-02 2013-12-04 Abbvie Inc Protéines thérapeutiques de liaison à dll4
CN106267189B (zh) * 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂

Also Published As

Publication number Publication date
NZ702288A (en) 2016-12-23
CL2014003237A1 (es) 2015-07-10
US9675692B2 (en) 2017-06-13
MA37645A3 (fr) 2017-07-31
EA029779B1 (ru) 2018-05-31
CO7151478A2 (es) 2014-12-29
CA2872275A1 (fr) 2013-12-05
SI2854849T1 (en) 2018-05-31
PH12014502429A1 (en) 2015-01-12
DK2854849T3 (en) 2018-04-30
UY34842A (es) 2013-12-31
MX357146B (es) 2018-06-28
MX2014014363A (es) 2015-02-05
SG11201407171XA (en) 2014-11-27
US20130323260A1 (en) 2013-12-05
WO2013181486A1 (fr) 2013-12-05
EP2854849B1 (fr) 2018-02-28
CN104349791A (zh) 2015-02-11
MA37645B1 (fr) 2018-10-31
CA2872275C (fr) 2021-05-18
AU2013267301A1 (en) 2014-12-18
LT2854849T (lt) 2018-05-10
SMT201800216T1 (it) 2018-05-02
JP6144758B2 (ja) 2017-06-07
TW201400130A (zh) 2014-01-01
EP2854849A1 (fr) 2015-04-08
PT2854849T (pt) 2018-05-09
NO2887943T3 (fr) 2018-05-05
ES2668900T3 (es) 2018-05-23
EA201492186A1 (ru) 2015-08-31
PH12014502429B1 (en) 2015-01-12
KR20150033615A (ko) 2015-04-01
BR112014028997A2 (pt) 2017-07-25
HK1207305A1 (en) 2016-01-29
JP2015520173A (ja) 2015-07-16
IL235468A0 (en) 2014-12-31
TWI609696B (zh) 2018-01-01
AU2013267301B2 (en) 2018-02-08
PL2854849T3 (pl) 2018-07-31
AR092325A1 (es) 2015-04-15

Similar Documents

Publication Publication Date Title
JOP20180103A1 (ar) مركب صيدلاني
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201791717A1 (ru) Стабильные водные составы адалимумаба
EA201500926A1 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
EA201300388A1 (ru) Соединения замещенного бензамида
EA201400365A1 (ru) Новые тиопроизводные лактамов в качестве высокоактивных ингибиторов hdac и их применение в качестве лекарственных средств
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA201301061A1 (ru) Фармацевтическая композиция, содержащая инозит
EA201491471A1 (ru) Состав, содержащий антитело против ил-17
EA201492186A1 (ru) СОДЕРЖАЩИЕ АНТИТЕЛА К Dll4 СТАБИЛИЗИРОВАННЫЕ КОМПОЗИЦИИ
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201400444A1 (ru) Производные 2-оксопиперидинила
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
EA201171414A1 (ru) Ингибиторы белков семейства iap
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции
EA201492280A1 (ru) Стабильный состав пексиганана
EP2822607C0 (fr) Compositions contenant de l'alcool utiles en tant que combustibles solides et leurs procédés de fabrication